B.Riley raises Axsome Therapeutics price target on sales guidance

Axsome Therapeutics reported Q1 2026 revenue of $191 million, up 57% year over year and slightly above the $188 million consensus, while Auvelity net sales of $153.2 million beat expectations and drove a sharp raise in peak sales guidance to about $8 billion from a $4 billion midpoint. B.Riley lifted its price target to $300 from $230, with several other firms also raising targets after the results. The stock has risen 21% in the past week and is trading near its 52-week high as investors focus on expanded approval for Alzheimer’s disease agitation and upcoming 2026 catalysts.

Analysis

The market is still underpricing how quickly Axsome can re-rate from a single-asset depression story into a multi-indication commercial compounder. The key second-order effect is that every incremental validation on AUVELITY reduces the perceived probability that payers will treat the Alzheimer’s agitation launch as optional, which matters because the addressable pool is not the constraint anymore — execution and reimbursement are. That shifts the stock from a sentiment-driven biotech multiple toward a late-stage specialty pharma multiple, where upside can persist even after a sharp move if the launch data keep compounding.

The more interesting read-through is competitive: a stronger AUVELITY launch pressures adjacent CNS incumbents and makes smaller neurology companies more vulnerable to “category dominance” rather than just asset-by-asset competition. If Axsome proves it can scale a field force efficiently, the market will start extrapolating that operating leverage into later assets, which compresses the discount rate on pipeline optionality. Conversely, that same expectation creates fragility: any stumble in coverage, discontinuation, or launch pacing could trigger a larger de-rating than typical because the valuation now embeds near-flawless execution.

The main contrarian point is that the move may still be too conservative if the consensus is anchoring to a one-disease model instead of a platform model. But the flip side is that the stock now has crowded-positive ownership and is vulnerable to a “good but not enough” reaction on any future catalyst over the next 1-2 quarters. The setup is strongest into catalyst windows; after that, the asymmetry shifts from multiple expansion to execution risk, especially if investors start debating whether the guidance is share-grabbing or truly addressable-market expanding.

Key Decisions for Investors

• Stay long AXSM on pullbacks over the next 2-6 weeks; use weakness toward prior breakout levels to add, because the market is likely to reward launch validation more than near-term EPS noise.
• For higher convexity, buy AXSM call spreads into the June 2026 dementia-agitation launch window; favorable if coverage and uptake accelerate, with defined downside if the launch underwhelms.
• Pair trade: long AXSM / short a basket of slower-growth CNS or commercial-stage biotech names over the next 3-6 months, targeting relative multiple expansion as Axsome de-risks pipeline monetization.
• If already long, trim 20-30% after sharp post-catalyst extensions and redeploy only if prescription growth or payer coverage data confirm the launch thesis; this is a momentum-friendly name but execution gaps can reprice it fast.